GGHCX Mutual Fund

GGHCX Mutual Fund

NAV$40.88
See how much of GGHCX you already own
Just $25 once·$69/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Mar 31, 2026

Net Assets
$681M
Expense Ratio
1.07%
Dividend Yield (Current)
5.58%
Holdings
81
Inception Date
Aug 7, 1989
Fund Family
Invesco (US)
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+1.62%
1 Year+17.11%
3 Year+7.51%
5 Year+2.41%
10 Year+6.99%

Asset Allocation

Stocks: 95.79%
Cash: 4.21%
See how much of GGHCX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report is $25, once. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co.9.07%
JNJJohnson & Johnson - Common5.81%
AZN:LNAstraZeneca PLC4.34%
GILDGilead Sciences4.10%
ABBVAbbvie Inc.3.67%
Top 10 Concentration: 42.62%Report Date: Mar 31, 2026
Download all 81 holdings for GGHCX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
5.58%
Frequency
Annually
Latest Distribution
$9.93
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

GGHCX Mutual Fund Overview

GGHCX Mutual Fund (Invesco Health Care Fund Class A) is managed by Invesco (US) with $681.2M in net assets. GGHCX expense ratio is 1.07%, holding 81 positions across sectors including Health Care, Real Estate. Inception date: 1989-08-07.

GGHCX performance shows a YTD return of 1.62%. The 1-year return is 17.11% and the 5-year return is 2.41%. GGHCX dividend yield stands at 5.58%, paid annually.

GGHCX top holdings include Eli Lilly & Co. (9.1%), Johnson & Johnson - Common (5.8%), AstraZeneca PLC (4.3%), Gilead Sciences (4.1%), Abbvie Inc. (3.7%). Go to all GGHCX holdings, GGHCX sectors, or GGHCX dividends.

GGHCX can be compared against other funds. Use GGHCX overlap to find shared positions, or GGHCX vs another fund for a side-by-side view. GGHCX alternatives are available via the screener, along with tax-loss harvesting opportunities.